Home > Healthcare > Pharmaceuticals > Finished Drug Form > Central Nervous System Therapeutics Market

Central Nervous System Therapeutics Market Size

Report ID: GMI6097
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Central Nervous System Therapeutics Market Size

Central Nervous System Therapeutics Market size was anticipated to be worth USD 110.4 billion in 2022 and is expected to reach USD 238.8 billion by 2032, increasing at an 8% CAGR 2032. The rising prevalence of CNS disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and depression drives the demand for effective CNS therapeutics.

To get key market trends

Download Free Sample

Moreover, technological advancements in treatment approaches, increasing adoption of novel drug delivery systems, neuromodulation techniques, and personalized medicine. These advancements allow for more precise and effective drug delivery to the CNS, enhancing therapeutic outcomes and minimizing side effects.

Central Nervous System Therapeutics Market Report Attributes
Report Attribute	Details
Base Year:	2022
Central Nervous System Therapeutics Market Size in 2022:	USD 110.4 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	8%
2032 Value Projection:	USD 238.8 Billion
Historical Data for:	2018 to 2022
No. of Pages:	200
Tables, Charts & Figures:	348
Segments covered:	Disease, Drug type, Distribution Channel, and Region
Growth Drivers:	Increasing prevalence of CNS disorders Technological advancements in drug development Growing geriatric population Increasing healthcare expenditure Growing investments in R&D Increasing awareness about CNS disorders
Pitfalls & Challenges:	Adverse drug reactions and safety concerns Stringent regulatory requirements High development costs

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Central nervous system (CNS) therapeutics industry was worth USD 110.4 billion in 2022 and is projected to reach USD 238.8 billion by 2032 owing to the high prevalence of CNS disorders across the globe

The antidepressant drug type segment held 25.5% of the market share in 2022 and is poised to expand at 8.3% CAGR by 2032 attributed to the rising prevalence of mental health disorders globally.

North America CNS therapeutics industry size is anticipated to record 7.9% CAGR and reach USD 113.3 billion by 2032 attributed to the rising focus on technological advancements in healthcare in the region

Some of the prominent market players are Biogen, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Merck & Co., Astra Zeneca, Shire PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., and Pfizer, Inc.